7,395 Shares in Organon & Co. (NYSE:OGN) Purchased by Mather Group LLC.

Mather Group LLC. acquired a new position in Organon & Co. (NYSE:OGN) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 7,395 shares of the company’s stock, valued at approximately $139,000.

A number of other large investors have also modified their holdings of OGN. Lindbrook Capital LLC grew its position in Organon & Co. by 348.3% in the 4th quarter. Lindbrook Capital LLC now owns 1,838 shares of the company’s stock valued at $27,000 after buying an additional 1,428 shares in the last quarter. Gladius Capital Management LP grew its position in Organon & Co. by 65.1% in the 4th quarter. Gladius Capital Management LP now owns 2,176 shares of the company’s stock valued at $31,000 after buying an additional 858 shares in the last quarter. Tompkins Financial Corp grew its position in Organon & Co. by 450.7% in the 1st quarter. Tompkins Financial Corp now owns 2,412 shares of the company’s stock valued at $45,000 after buying an additional 1,974 shares in the last quarter. GAMMA Investing LLC bought a new position in Organon & Co. in the 4th quarter valued at about $38,000. Finally, Eagle Bay Advisors LLC boosted its position in shares of Organon & Co. by 100.0% during the 4th quarter. Eagle Bay Advisors LLC now owns 2,800 shares of the company’s stock valued at $40,000 after purchasing an additional 1,400 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Price Performance

OGN stock opened at $20.46 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.15 and a debt-to-equity ratio of 181.35. Organon & Co. has a one year low of $10.84 and a one year high of $24.08. The firm has a market capitalization of $5.26 billion, a PE ratio of 5.00, a P/E/G ratio of 0.89 and a beta of 0.87. The firm has a 50-day moving average of $20.06 and a two-hundred day moving average of $17.62.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.31. Organon & Co. had a net margin of 16.50% and a negative return on equity of 360.57%. The company had revenue of $1.62 billion during the quarter, compared to analyst estimates of $1.57 billion. On average, analysts forecast that Organon & Co. will post 4.3 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 13th. Shareholders of record on Monday, May 13th were paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 5.47%. The ex-dividend date of this dividend was Friday, May 10th. Organon & Co.’s dividend payout ratio is presently 27.38%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on OGN. The Goldman Sachs Group raised their price objective on shares of Organon & Co. from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Piper Sandler raised their price objective on shares of Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, April 29th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.